403 related articles for article (PubMed ID: 23090595)
1. Current and future challenges in the development of antimicrobial agents.
Rennie RP
Handb Exp Pharmacol; 2012; (211):45-65. PubMed ID: 23090595
[TBL] [Abstract][Full Text] [Related]
2. [Gram-positive bacterial infections resistant to antibiotic treatment].
Utili R
Ann Ital Med Int; 2001; 16(4):205-19. PubMed ID: 11799629
[TBL] [Abstract][Full Text] [Related]
3. [The history of the development and changes of quinolone antibacterial agents].
Takahashi H; Hayakawa I; Akimoto T
Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
[TBL] [Abstract][Full Text] [Related]
4. Tigecycline: first of a new class of antimicrobial agents.
Rose WE; Rybak MJ
Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial resistance trends among 5608 clinical Gram-positive isolates in China: results from the Gram-Positive Cocci Resistance Surveillance program (2005-2010).
Zhao C; Sun H; Wang H; Liu Y; Hu B; Yu Y; Sun Z; Chu Y; Cao B; Liao K; Lei J; Hu Z; Zhang L; Zhang X; Xu Y; Wang Z; Chen M
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):174-81. PubMed ID: 22521693
[TBL] [Abstract][Full Text] [Related]
7. Trends in antimicrobial resistance among today's bacterial pathogens.
Thornsberry C
Pharmacotherapy; 1995; 15(1 Pt 2):3S-8S. PubMed ID: 7753690
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
9. Optimizing therapy for vancomycin-resistant enterococci (VRE).
Linden PK
Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Tigecycline.
Pankey GA
J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial resistance in Europe and its potential impact on empirical therapy.
Rossolini GM; Mantengoli E
Clin Microbiol Infect; 2008 Dec; 14 Suppl 6():2-8. PubMed ID: 19040461
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Infect Control; 2006 Jun; 34(5 Suppl 1):S11-9; discussion S64-73. PubMed ID: 16813977
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
[TBL] [Abstract][Full Text] [Related]
15. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial resistance in gram-positive bacteria.
Rice LB
Am J Med; 2006 Jun; 119(6 Suppl 1):S11-9; discussion S62-70. PubMed ID: 16735146
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of ertapenem: review of recent studies.
Wexler HM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii11-21. PubMed ID: 15150179
[TBL] [Abstract][Full Text] [Related]
18. [Review of oral cephalosporins. Basis for a rational choice].
Forti IN
Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Jones RN; Pfaller MA
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]